Transaction #20595 · Form 4 · 0001213900-25-121974
RELMADA THERAPEUTICS, INC. · Stock award · Stock Appreciation Rights
RELMADA THERAPEUTICS, INC. · Transacted December 12, 2025 · Filed December 16, 2025
What does this filing report?
An SEC Form 4 filing for RELMADA THERAPEUTICS, INC. records a stock award involving Stock Appreciation Rights on December 12, 2025. The reported quantity was 1,198,000. The filing date is December 16, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- RELMADA THERAPEUTICS, INC.
- Company CIK
- 0001553643
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 1,198,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 1,198,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 16, 2025, 9:30 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- TRAVERSA SERGIO ↗
Chief Executive Officer · Director
CIK 0001565832
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 1,198,000
- Conversion / exercise price
- 4.06
- Exercise date
- March 12, 2026
- Expiration date
- December 12, 2035
Filing footnotes & remarks
- F1
- The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- F2
- Purchase prices range from $4.10 to $4.12 per share, inclusive.
- F3
- The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.